Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Not all that glitters is gold: A simple clinical score to unmask adverse SF3B1WT MDS-RS with low blast count

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMaría Diez‐CampeloFAFrancesco Annunziato

Discussion

Loading...

Member takes

Overview

Analysis identifies bone marrow features linked to poor progression free survival in SF3B1WT MDS-RS cases, suggesting targeted monitoring strategies.

Key Points

  • Worse progression free survival is observed in SF3B1WT cases compared to SF3B1MUT, indicating a need for closer monitoring.
  • The method involved a predictive score based on clinical and morphologic parameters to identify high-risk MDS-RS cases.
  • Critical bone marrow features include lower platelet counts and more multilineage dysplasia in SF3B1WT cases.
  • This research highlights the potential impact of personalized approaches in managing adverse genetic profiles of MDS-RS.

Cite This Study

Diez‐Campelo et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da35https://doi.org/10.1182/blood-2025-5623
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictive value of red cell distribution width for SF3B1 mutation status in myelodysplastic neoplasms2025
  2. 2Clinical characteristics and molecular profiling of SF3B1-mutated myelodysplastic syndrome (MDS) in a real-world practice2025
  3. 3The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms2025
  4. 4From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS2025
  5. 5Transfusion dependence is associated with poor survival in MDS-h and MDS-LB, while transplantation improves outcomes2025